Brook Saunders, MD
Gynecologic Oncology · Knoxville, TNNPI 1851475602
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by GSK at 33.5% of the total. Reporting peaked in 2023 at $364 and has fallen 71.2% since, to $105 in 2024. That places this record below the midpoint for gynecologic oncology clinicians in TN, where the typical reported total is $3,700.
Across 41 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$299
- Intuitive Surgical$171
- AstraZeneca$77
- Regeneron Healthcare Solutions, Inc.$55
- Takeda Pharmaceuticals U.S.A., Inc.$42
- Genentech USA, Inc.$40
- plus $209 from 9 others
What the payments were for
- Food & beverage$87298%
- Education$202%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 16 | $299 |
| Intuitive Surgical | 3 | $171 |
| AstraZeneca | 4 | $77 |
| Regeneron Healthcare Solutions, Inc. | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Genentech USA, Inc. | 2 | $40 |
| Morphosys, US Inc. | 2 | $36 |
| Amgen | 2 | $34 |
| Seagen Inc. | 1 | $23 |
| Puma Biotechnology, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $22 |
| Clovis Oncology, Inc. | 2 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Myriad Genetic Laboratories, Inc. | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
How this compares
$892 in reported general payments places this provider in the 20th percentile of 40 gynecologic oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 39 | $669 |
| Medroxyprogesterone Acetate | 15 | $489 |
| Estradiol | 14 | $368 |
| Ondansetron Hcl | 42 | $268 |
| Promethazine Hcl | 22 | $123 |
| Oxycodone Hcl | 26 | $49 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Knoxville
- Larry KilgoreKnoxville$7K
- Jonathan BooneKnoxville$4K
- Kristopher KimballKnoxville$4K
- David MartinKnoxville$1K
- Kenneth CoferKnoxville$390
- Don HallKnoxville$30
- Todd TillmannsGermantown$127K
- Ronald AlvarezNashville$33K
- Adam ElnaggarGermantown$29K
- Michael StanyNashville$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.